Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MITF | O75030 | 1/20 | 0.67 |
| ▸ | XBP1 | P17861 | 1/20 | 0.67 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.67 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240482 | 0.91 | TRPV1 (0.61) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL860101 | 0.89 | TRPV1 (0.58) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL846578 | 0.84 | TRPV1 (0.67) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL846396 | 0.83 | TRPV1 (1.00) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL6817067 | 0.83 | NAMPT (0.61) | NPC1RAB9AALDH1A1NAMPTSMN1; SMN2 | |
| SCHEMBL27894588 | 0.82 | MAP4K4 (0.53) | TRPV1NPC1RAB9AKDM4ENAMPT | |
| SCHEMBL846874 | 0.82 | NPC1 (0.78) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL19616647 | 0.81 | NPC1 (0.76) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL846216 | 0.80 | NPC1 (1.00) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL995474 | 0.80 | KDR (1.00) | TRPV1NPC1RAB9AKDM4EMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-1603883-B1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2308848-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | Janssen Pharmaceutica NV (BE) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308848-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | Janssen Pharmaceutica NV (BE) | 2011-04-13 | — | — | EP | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| EP-1603883-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-14 | — | — | EP | disclosed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | disclosed |
| WO-2004069792-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | TRPV1 1/4885NPC1 1518/4885RAB9A 2453/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | TRPV1 1/4885NPC1 1518/4885RAB9A 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.